ANIPANI PHARMACEUTICALS INC

Nasdaq anipharmaceuticals.com


$ 65.62 $ -1.10 (-1.65 %)    

Wednesday, 08-May-2024 15:59:59 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 65.62
$ 66.62
$ 0.00 x 0
$ 0.00 x 0
$ 65.36 - $ 67.18
$ 38.91 - $ 70.81
161,262
na
1.19B
$ 0.86
$ 69.60
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-29-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-01-2021 09-30-2021 10-Q
11 08-06-2021 06-30-2021 10-Q
12 05-07-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-27-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-03-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 03-02-2017 12-31-2016 10-K
30 11-03-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 02-23-2016 12-31-2015 10-K
34 11-03-2015 09-30-2015 10-Q
35 08-04-2015 06-30-2015 10-Q
36 05-05-2015 03-31-2015 10-Q
37 02-23-2015 12-31-2014 10-K
38 11-10-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-reiterates-buy-on-ani-pharmaceuticals-maintains-77-price-target

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $77 price target.

 ani-pharmaceuticals-announces-the-launch-of-baclofen-oral-suspension

U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.

 ani-pharmaceuticals-announces-the-launch-of-levofloxacin-oral-solution-usp

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Levofloxacin Oral Solution, a generi...

 capital-one-initiates-coverage-on-ani-pharmaceuticals-with-overweight-rating

Capital One analyst Timothy Chiang initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Overweight rating.

 alphabet-dover-and-2-other-stocks-insiders-are-selling

The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

 guggenheim-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-77

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $70 t...

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-83

HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...

 truist-securities-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-80

Truist Securities analyst Gregory Fraser maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target ...

 ani-pharmaceuticals-q4-adjusted-eps-100-beats-085-estimate-sales-13165m-beat-12221m-estimate

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 ani-pharmaceuticals-announced-the-launch-of-pentoxifylline-extended-release-tablets-usp-400-mg

ANI's Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug Trental. The current annual U.S. marke...

 ani-pharma-bags-fda-approval-and-launch-of-indomethacin-oral-suspension-usp

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received U.S. Food and Drug Administration...

 why-is-generic-drug-player-ani-pharmaceuticals-stock-trading-lower-today

ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION